<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39287389</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Vascular endothelial growth factor receptor 2 as a potential host target for the inhibition of enterovirus replication.</ArticleTitle><Pagination><StartPage>e0112924</StartPage><MedlinePgn>e0112924</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e01129-24</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/jvi.01129-24</ELocationID><Abstract><AbstractText Label="UNLABELLED">Because host kinases are key regulators of multiple signaling pathways in response to viral infections, we previously screened a kinase inhibitor library using rhabdomyosarcoma cells and human intestinal organoids in parallel to identify potent inhibitors against EV-A71 infection. We found that Rho-associated coiled-coil-containing protein kinase (Rock) inhibitor efficiently suppressed the EV-A71 replication and further revealed Rock1 as a novel EV-A71 host factor. In this study, subsequent analysis found that a variety of vascular endothelial growth factor receptor (VEGFR) inhibitors also had potent antiviral effects. Among the hits, Pazopanib, with a selectivity index as high as 254, which was even higher than that of Pirodavir, a potent broad-spectrum picornavirus inhibitor targeting viral capsid protein VP1, was selected for further analysis. We demonstrated that Pazopanib not only efficiently suppressed the replication of EV-A71 in a dose-dependent manner, but also exhibited broad-spectrum anti-enterovirus activity. Mechanistically, Pazopanib probably induces alterations in host cells, thereby impeding viral genome replication and transcription. Notably, VEGFR2 knockdown and overexpression suppressed and facilitated EV-A71 replication, respectively, indicating that VEGFR2 is a novel host dependency factor for EV-A71 replication. Transcriptome analysis further proved that VEGFR2 potentially plays a crucial role in combating EV-A71 infection through the TSAd-Src-PI3K-Akt pathway. These findings expand the range of potential antiviral candidates of anti-enterovirus therapeutics and suggest that VEGFR2 may be a key host factor involved in EV-A71 replication, making it a potential target for the development of anti-enterovirus therapeutics.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">As the first clinical case was identified in the United States, EV-A71, a significant neurotropic enterovirus, has been a common cause of hand, foot, and mouth disease (HFMD) in infants and young children. Developing an effective antiviral agent for EV-A71 and other human enteroviruses is crucial, as these viral pathogens consistently cause outbreaks in humans. In this study, we demonstrated that multiple inhibitors against VEGFRs effectively reduced EV-A71 replication, with Pazopanib emerging as the top candidate. Furthermore, Pazopanib also attenuated the replication of other enteroviruses, including CVA10, CVB1, EV-D70, and HRV-A, displaying broad-spectrum anti-enterovirus activity. Given that Pazopanib targets various VEGFRs, we narrowed the focus to VEGFR2 using knockdown and overexpression experiments. Transcriptomic analysis suggests that Pazopanib's potential downstream targets involve the TSAd-Src-PI3K-Akt pathway. Our work may contribute to identifying targets for antiviral inhibitors and advancing treatments for human enterovirus infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-0347-9104</Identifier><AffiliationInfo><Affiliation>Shanghai Sci-Tech Inno Center for Infection &amp; Immunity, National Medical Center for Infectious Diseases, Huashan Hospital, Institute of Infection and Health, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Qiao</LastName><ForeName>Rui</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0210-2863</Identifier><AffiliationInfo><Affiliation>Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hao</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Greater Bay Area Institute of Precision Medicine (Guangzhou), Fudan University, Nansha District, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xu</LastName><ForeName>Longfa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yinying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Sci-Tech Inno Center for Infection &amp; Immunity, National Medical Center for Infectious Diseases, Huashan Hospital, Institute of Infection and Health, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiayan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Human Phenome Institute, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenhong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jincun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2515-5589</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou Laboratory, Bio-Island, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Pengfei</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2454-7652</Identifier><AffiliationInfo><Affiliation>Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2023YFC2605400,2023YFC3404000</GrantID><Agency>MOST | National Key Research and Development Program of China (NKPs)</Agency><Country /></Grant><Grant><GrantID>32300121</GrantID><Agency>MOST | National Natural Science Foundation of China (NSFC)</Agency><Country /></Grant><Grant><GrantID>32300533</GrantID><Agency>MOST | National Natural Science Foundation of China (NSFC)</Agency><Country /></Grant><Grant><GrantID>32270142</GrantID><Agency>MOST | National Natural Science Foundation of China (NSFC)</Agency><Country /></Grant><Grant><GrantID>23PJD007</GrantID><Agency>Shanghai Pujiang Programme</Agency><Country /></Grant><Grant><GrantID>23410760500</GrantID><Agency>Programme of Science and Technology Cooperation with Hong Kong, Macao and Taiwan</Agency><Country /></Grant><Grant><GrantID>No. SKLGE-2304</GrantID><Agency>Open Research Fund of State Key Laboratory of Genetic Engineering</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007191">Indazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C000588866">KDR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>BML697718K</RegistryNumber><NameOfSubstance UI="C074589">pirodavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="Y">Pyrimidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040301" MajorTopicYN="Y">Vascular Endothelial Growth Factor Receptor-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007191" MajorTopicYN="N">Indazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV-A71</Keyword><Keyword MajorTopicYN="N">VEGFR family</Keyword><Keyword MajorTopicYN="N">VEGFR2</Keyword><Keyword MajorTopicYN="N">host factor</Keyword><Keyword MajorTopicYN="N">kinase inhibitors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>21</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>9</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39287389</ArticleId><ArticleId IdType="pmc">PMC11542593</ArticleId><ArticleId IdType="doi">10.1128/jvi.01129-24</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yeung ML, Jia L, Yip CCY, Chan JFW, Teng JLL, Chan K-H, Cai J-P, Zhang C, Zhang AJ, Wong W-M, Kok K-H, Lau SKP, Woo PCY, Lo JYC, Jin D-Y, Shih S-R, Yuen K-Y. 2018. Human tryptophanyl-tRNA synthetase is an IFN-γ–inducible entry factor for Enterovirus. J Clin Invest 128:5163–5177. doi:10.1172/JCI99411</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99411</ArticleId><ArticleId IdType="pmc">PMC6205371</ArticleId><ArticleId IdType="pubmed">30153112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li Y. 2019. Recent progress on functional genomics research of enterovirus 71. Virol Sin 34:9–21. doi:10.1007/s12250-018-0071-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-018-0071-9</ArticleId><ArticleId IdType="pmc">PMC6420560</ArticleId><ArticleId IdType="pubmed">30552635</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778–790. doi:10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Stratov I, Nagarajan L, Davis S. 2001. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32:236–242. doi:10.1086/318454</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/318454</ArticleId><ArticleId IdType="pubmed">11170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Nakashima K. 2014. Surveillance of hand, foot, and mouth disease for a vaccine. Lancet Infect Dis 14:262–263. doi:10.1016/S1473-3099(13)70330-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70330-X</ArticleId><ArticleId IdType="pubmed">24485992</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C-Y, Liu C-C. 2018. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vaccines 17:819–831. doi:10.1080/14760584.2018.1510326</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1510326</ArticleId><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. 2015. Targeting cancer with kinase inhibitors. J Clin Invest 125:1780–1789. doi:10.1172/JCI76094</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI76094</ArticleId><ArticleId IdType="pmc">PMC4463189</ArticleId><ArticleId IdType="pubmed">25932675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId><ArticleId IdType="pubmed">21376230</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamatsu Y, Krähling V, Kolesnikova L, Halwe S, Lier C, Baumeister S, Noda T, Biedenkopf N, Becker S. 2020. Serine-arginine protein kinase 1 regulates Ebola virus transcription. mBio 11:e02565-19. doi:10.1128/mBio.02565-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02565-19</ArticleId><ArticleId IdType="pmc">PMC7042693</ArticleId><ArticleId IdType="pubmed">32098814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieczkarski SB, Brown HA, Whittaker GR. 2003. Role of protein kinase C βII in influenza virus entry via late endosomes. J Virol 77:460–469. doi:10.1128/jvi.77.1.460-469.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.1.460-469.2003</ArticleId><ArticleId IdType="pmc">PMC140583</ArticleId><ArticleId IdType="pubmed">12477851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li K, Cui B, Yan H, Wu S, Wang K, Yang G, Jiang J, Li Y. 2024. Tribbles pseudokinase 3 promotes enterovirus A71 infection via dual mechanisms. Emerg Microbes Infect 13:2307514. doi:10.1080/22221751.2024.2307514</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2024.2307514</ArticleId><ArticleId IdType="pmc">PMC10829831</ArticleId><ArticleId IdType="pubmed">38240287</ArticleId></ArticleIdList></Reference><Reference><Citation>Leong SY, Ong BKT, Chu JJH. 2015. The role of misshapen NCK-related kinase (MINK), a novel Ste20 family kinase, in the IRES-mediated protein translation of human enterovirus 71. PLoS Pathog 11:e1004686. doi:10.1371/journal.ppat.1004686</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004686</ArticleId><ArticleId IdType="pmc">PMC4352056</ArticleId><ArticleId IdType="pubmed">25747578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Li C, Chiu MC, Qiao R, Jiang S, Wang P, Zhou J. 2022. Rock1 is a novel host dependency factor of human enterovirus A71: implication as a drug target. J Med Virol 94:5415–5424. doi:10.1002/jmv.27975</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27975</ArticleId><ArticleId IdType="pubmed">35791459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669–676. doi:10.1038/nm0603-669</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0603-669</ArticleId><ArticleId IdType="pubmed">12778165</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Yan J, Liu B. 2018. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 9:978. doi:10.3389/fimmu.2018.00978</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00978</ArticleId><ArticleId IdType="pmc">PMC5943566</ArticleId><ArticleId IdType="pubmed">29774034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K. 2007. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol Biol 14:249–250. doi:10.1038/nsmb1202</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb1202</ArticleId><ArticleId IdType="pubmed">17293873</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma M, Biziato D, Petrova TV. 2017. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17:457–474. doi:10.1038/nrc.2017.51</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2017.51</ArticleId><ArticleId IdType="pubmed">28706266</ArticleId></ArticleIdList></Reference><Reference><Citation>Apte RS, Chen DS, Ferrara N. 2019. VEGF in signaling and disease: beyond discovery and development. Cell 176:1248–1264. doi:10.1016/j.cell.2019.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.01.021</ArticleId><ArticleId IdType="pmc">PMC6410740</ArticleId><ArticleId IdType="pubmed">30849371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuest TR, Carr DJJ. 2010. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. J Exp Med 207:101–115. doi:10.1084/jem.20091385</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20091385</ArticleId><ArticleId IdType="pmc">PMC2812544</ArticleId><ArticleId IdType="pubmed">20026662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbunova EE, Gavrilovskaya IN, Pepini T, Mackow ER. 2011. VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. J Virol 85:2296–2303. doi:10.1128/JVI.02319-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02319-10</ArticleId><ArticleId IdType="pmc">PMC3067787</ArticleId><ArticleId IdType="pubmed">21177802</ArticleId></ArticleIdList></Reference><Reference><Citation>Park PJ, Chang M, Garg N, Zhu J, Chang J-H, Shukla D. 2015. Corneal lymphangiogenesis in herpetic stromal keratitis. Surv Ophthalmol 60:60–71. doi:10.1016/j.survophthal.2014.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.survophthal.2014.06.001</ArticleId><ArticleId IdType="pmc">PMC4262646</ArticleId><ArticleId IdType="pubmed">25444520</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y, Wu W, Wan Y, Li L, Zhang J, Chen X, Liu S, Yao X. 2021. Brivanib alaninate inhibited dengue virus proliferation through VEGFR2/AMPK pathway. Pharmacol Res 170:105721. doi:10.1016/j.phrs.2021.105721</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105721</ArticleId><ArticleId IdType="pubmed">34116207</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao R, Tang W, Li J, Li C, Zhao C, Wang X, Li M, Cui Y, Chen Y, Cai G, Wu Q, Zhao X, Wang P. 2023. Structure-based virtual screening of ROCK1 inhibitors for the discovery of enterovirus-A71 antivirals. Virol (Auckl) 585:205–214. doi:10.1016/j.virol.2023.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2023.06.011</ArticleId><ArticleId IdType="pubmed">37384967</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Chu H, Wong B-Y, Chiu MC, Wang D, Li C, Liu X, Yang D, Poon V-M, Cai J, Chan J-W, To K-W, Zhou J, Yuen K-Y. 2020. Activation of C-type lectin receptor and (RIG)-I-like receptors contributes to proinflammatory response in Middle East respiratory syndrome coronavirus-infected macrophages. J Infect Dis 221:647–659. doi:10.1093/infdis/jiz483</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz483</ArticleId><ArticleId IdType="pmc">PMC7107474</ArticleId><ArticleId IdType="pubmed">31562757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang J-L, Zhou J, Zhao X, Li C, Zou Z, Yin F, Yuan S, Yeung M-L, Chu H, Chan J-W. 2021. Development of three-dimensional human intestinal organoids as a physiologically relevant model for characterizing the viral replication kinetics and antiviral susceptibility of enteroviruses. Biomedicines 9:88. doi:10.3390/biomedicines9010088</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9010088</ArticleId><ArticleId IdType="pmc">PMC7831294</ArticleId><ArticleId IdType="pubmed">33477611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Wang P, Zhu G, Wang B, Zhu G. 2014. Enzymatic characterization of a type II isocitrate dehydrogenase from pathogenic Leptospira interrogans serovar Lai strain 56601. Appl Biochem Biotechnol 172:487–496. doi:10.1007/s12010-013-0521-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12010-013-0521-7</ArticleId><ArticleId IdType="pubmed">24092452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Li C, Liu X, Chiu MC, Wang D, Wei Y, Chu H, Cai J-P, Hau-Yee Chan I, Kak-Yuen Wong K, Fuk-Woo Chan J, Kai-Wang To K, Yuen KY, Zhou J. 2021. Human intestinal organoids recapitulate enteric infections of enterovirus and coronavirus. Stem Cell Reports 16:493–504. doi:10.1016/j.stemcr.2021.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.02.009</ArticleId><ArticleId IdType="pmc">PMC7940440</ArticleId><ArticleId IdType="pubmed">33626333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Qiu T, Huang X, Mao Q, Wang Y, Qiao R, Li J, Mao T, Wang Y, Cun Y, et al. . 2024. Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination. Cell Discov 10:14. doi:10.1038/s41421-024-00648-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-024-00648-1</ArticleId><ArticleId IdType="pmc">PMC10847457</ArticleId><ArticleId IdType="pubmed">38320990</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray NL, Pimentel H, Melsted P, Pachter L. 2016. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34:525–527. doi:10.1038/nbt.3519</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3519</ArticleId><ArticleId IdType="pubmed">27043002</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson C, Love MI, Robinson MD. 2015. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4:1521. doi:10.12688/f1000research.7563.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.7563.2</ArticleId><ArticleId IdType="pmc">PMC4712774</ArticleId><ArticleId IdType="pubmed">26925227</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. doi:10.1186/s13059-014-0550-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. 2019. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10:1523. doi:10.1038/s41467-019-09234-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09234-6</ArticleId><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia K-S, Li W-T, Chang C-M, Hsu M-C, Chern J-H, Leong MK, Tseng S-N, Lee C-C, Lee Y-C, Chen S-J, Peng K-C, Tseng H-Y, Chang Y-L, Tai C-L, Shih S-R. 2002. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem 45:1644–1655. doi:10.1021/jm010536a</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm010536a</ArticleId><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Chik K-H, Chan J-W, Cai J-P, Cao H, Tsang J-L, Zou Z, Hung Y-P, Tang K, Jia L, Luo C, Yin F, Ye Z-W, Chu H, Yeung M-L, Yuan S. 2022. Vemurafenib inhibits enterovirus A71 genome replication and virus assembly. Pharmaceuticals (Basel) 15:1067. doi:10.3390/ph15091067</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15091067</ArticleId><ArticleId IdType="pmc">PMC9500672</ArticleId><ArticleId IdType="pubmed">36145288</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J-R, Tuan Y-C, Tsai H-P, Yan J-J, Liu C-C, Su I-J. 2002. Change of major genotype of enterovirus 71 in outbreaks of hand-foot-and-mouth disease in Taiwan between 1998 and 2000. J Clin Microbiol 40:10–15. doi:10.1128/JCM.40.1.10-15.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.40.1.10-15.2002</ArticleId><ArticleId IdType="pmc">PMC120096</ArticleId><ArticleId IdType="pubmed">11773085</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Zhu G, Qiu F, Ren F, Lin B, Zhang D, Yang Q, Huang C. 2023. PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling. Virol Sin 38:276–284. doi:10.1016/j.virs.2023.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virs.2023.01.006</ArticleId><ArticleId IdType="pmc">PMC10176437</ArticleId><ArticleId IdType="pubmed">36669700</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo D, Yu X, Wang D, Li Z, Zhou Y, Xu G, Yuan B, Qin Y, Chen M. 2022. SLC35B2 acts in a dual role in the host sulfation required for EV71 infection. J Virol 96:e0204221. doi:10.1128/jvi.02042-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02042-21</ArticleId><ArticleId IdType="pmc">PMC9093107</ArticleId><ArticleId IdType="pubmed">35420441</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KX, Phuektes P, Kumar P, Goh GYL, Moreau D, Chow VTK, Bard F, Chu JJH. 2016. Human genome-wide RNAi screen reveals host factors required for enterovirus 71 replication. Nat Commun 7:13150. doi:10.1038/ncomms13150</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13150</ArticleId><ArticleId IdType="pmc">PMC5071646</ArticleId><ArticleId IdType="pubmed">27748395</ArticleId></ArticleIdList></Reference><Reference><Citation>Min N, Leong PT, Lee RCH, Khuan JSE, Chu JJH. 2018. A flavonoid compound library screen revealed potent antiviral activity of plant-derived flavonoids on human enterovirus A71 replication. Antiviral Res 150:60–68. doi:10.1016/j.antiviral.2017.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.12.003</ArticleId><ArticleId IdType="pubmed">29233744</ArticleId></ArticleIdList></Reference><Reference><Citation>Blutt SE, Crawford SE, Ramani S, Zou WY, Estes MK. 2018. Engineered human gastrointestinal cultures to study the microbiome and infectious diseases. Cell Mol Gastroenterol Hepatol 5:241–251. doi:10.1016/j.jcmgh.2017.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2017.12.001</ArticleId><ArticleId IdType="pmc">PMC5904028</ArticleId><ArticleId IdType="pubmed">29675450</ArticleId></ArticleIdList></Reference><Reference><Citation>Roskoski Jr R. 2020. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 152:104609. doi:10.1016/j.phrs.2019.104609</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2019.104609</ArticleId><ArticleId IdType="pubmed">31862477</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan Y, Yuan Q, Wang Q, Compton S, Wu D, Tang W. 2022. Pazopanib is a potential treatment for coronavirus-induced lung injuries. J Immunol 209:723–730. doi:10.4049/jimmunol.2100968</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100968</ArticleId><ArticleId IdType="pmc">PMC9378470</ArticleId><ArticleId IdType="pubmed">35914834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel M-C, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M. 2007. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6:2012–2021. doi:10.1158/1535-7163.MCT-07-0193</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-07-0193</ArticleId><ArticleId IdType="pubmed">17620431</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S, Kakutani S, Sato Y, Hanashi A, Kinoshita Y, Ishikawa A. 2018. Drug review: pazopanib. Jpn J Clin Oncol 48:503–513. doi:10.1093/jjco/hyy053</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jjco/hyy053</ArticleId><ArticleId IdType="pubmed">29684209</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L. 2023. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 8:198. doi:10.1038/s41392-023-01460-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01460-1</ArticleId><ArticleId IdType="pmc">PMC10175505</ArticleId><ArticleId IdType="pubmed">37169756</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaik F, Cuthbert GA, Homer-Vanniasinkam S, Muench SP, Ponnambalam S, Harrison MA. 2020. Structural basis for vascular endothelial growth factor receptor activation and implications for disease therapy. Biomolecules 10:1673. doi:10.3390/biom10121673</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10121673</ArticleId><ArticleId IdType="pmc">PMC7765180</ArticleId><ArticleId IdType="pubmed">33333800</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya M. 2011. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2:1097–1105. doi:10.1177/1947601911423031</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1947601911423031</ArticleId><ArticleId IdType="pmc">PMC3411125</ArticleId><ArticleId IdType="pubmed">22866201</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. 2011. Signal transduction by vascular endothelial growth factor receptors. Biochem J 437:169–183. doi:10.1042/BJ20110301</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20110301</ArticleId><ArticleId IdType="pubmed">21711246</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>